Search

Your search keyword '"Al-Khalidi, Hussein R."' showing total 561 results
Start Over Author "Al-Khalidi, Hussein R."
561 results on '"Al-Khalidi, Hussein R."'

2. Effects of an Intervention to Improve Evidence-Based Care for People With Diabetes and Cardiovascular Disease Across Sex, Race, and Ethnicity Subgroups: Insights From the COORDINATE-Diabetes Trial

Author

Tannu, Manasi, Kaltenbach, Lisa, Pagidipati, Neha J., McGuire, Darren K., Aroda, Vanita R., Pop-Busui, Rodica, Kondamudi, Nitin, Al-Khalidi, Hussein R., Lopes, Renato D., Cavender, Matthew A., Nelson, Adam J., Kirk, Julienne, Lingvay, Ildiko, Magwire, Melissa, Richardson, Caroline Regina, Webb, Laura, Leyva, Monica, Pandey, Ambarish, Washington, Alana, Pak, Jonathan, Gaynor, Tanya, Khan, Waqar, Weston, Patrick, Granger, Christopher B., and Green, Jennifer

Published
2024
Full Text
View/download PDF

4. RAndomized Cluster Evaluation of Cardiac ARrest Systems (RACE-CARS) trial: Study rationale and design

Author

Krychtiuk, Konstantin A., Starks, Monique A., Al-Khalidi, Hussein R., Mark, Daniel B., Monk, Lisa, Yow, Eric, Kaltenbach, Lisa, Jollis, James G., Al-Khatib, Sana M., Bosworth, Hayden B., Ward, Kimberly, Brady, Sarah, Tyson, Clark, Vandeventer, Steve, Baloch, Khaula, Oakes, Megan, Blewer, Audrey L., Lewinski, Allison A., Hansen, Carolina Malta, Sharpe, Edward, Rea, Thomas D., Nelson, R. Darrell, Sasson, Comilla, McNally, Bryan, and Granger, Christopher B.

Published
2024
Full Text
View/download PDF

8. Copula-Frailty Models for Recurrent Event Data Based on Monte Carlo EM Algorithm

Author

Bedair, Khaled F., Hong, Yili, and Al-Khalidi, Hussein R.

Subjects
Statistics - Methodology, Statistics - Computation
Abstract

Multi-type recurrent events are often encountered in medical applications when two or more different event types could repeatedly occur over an observation period. For example, patients may experience recurrences of multi-type nonmelanoma skin cancers in a clinical trial for skin cancer prevention. The aims in those applications are to characterize features of the marginal processes, evaluate covariate effects, and quantify both the within-subject recurrence dependence and the dependence among different event types. We use copula-frailty models to analyze correlated recurrent events of different types. Parameter estimation and inference are carried out by using a Monte Carlo expectation-maximization (MCEM) algorithm, which can handle a relatively large (i.e., three or more) number of event types. Performances of the proposed methods are evaluated via extensive simulation studies. The developed methods are used to model the recurrences of skin cancer with different types.

Published
2021

14. Patients’ Experiences With the Removal of a Ureteral Stent: Insights From In-depth Interviews With Participants in the USDRN STENTS Qualitative Cohort Study

Author

Dombeck, Carrie, Scales, Charles D., McKenna, Kevin, Swezey, Teresa, Harper, Jonathan D., Antonelli, Jodi A., Desai, Alana C., Lai, H. Henry, McCune, Rebecca, Curatolo, Michele, Al-Khalidi, Hussein R., Maalouf, Naim M., Reese, Peter P., Wessells, Hunter, Kirkali, Ziya, and Corneli, Amy

Published
2023
Full Text
View/download PDF

15. Coordinating Cardiology clinics randomized trial of interventions to improve outcomes (COORDINATE) – Diabetes: rationale and design

Author

Nelson, Adam J., Pagidipati, Neha J., Kelsey, Michelle D., Ardissino, Maddalena, Aroda, Vanita R., Cavender, Matthew A., Lopes, Renato D., Al-Khalidi, Hussein R., Braceras, Rogelio, Gaynor, Tanya, Kaltenbach, Lisa A., Kirk, Julienne K., Lingvay, Ildiko, Magwire, Melissa L., O'Brien, Emily C., Pak, Jonathan, Pop-Busui, Rodica, Richardson, Caroline R., Levya, Monica, Senyucel, Cagri, Webb, Laura, McGuire, Darren K., Green, Jennifer B., and Granger, Christopher B.

Published
2023
Full Text
View/download PDF

16. Optimal medical therapy with or without surgical revascularization and long-term outcomes in ischemic cardiomyopathy

Author

Dabrowski, Rafal, Djokovic, Ljubomir, Drazner, Mark, Haddad, Haissam, Ali, Imtiaz S., Keltai, Matyas, Naik, Ajay, Sopko, George, Golba, Krzysztof, Andersson, Bert, Carson, Peter, Kukulski, Tomasz, Farsky, Pedro S., White, Jennifer, Al-Khalidi, Hussein R., Sueta, Carla A., Rouleau, Jean L., Panza, Julio A., Velazquez, Eric J., and O'Connor, Christopher M.

Published
2022
Full Text
View/download PDF

21. Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial

Author

Pokorney, Sean D., Chertow, Glenn M., Al-Khalidi, Hussein R., Gallup, Dianne, Dignacco, Pat, Mussina, Kurt, Bansal, Nisha, Gadegbeku, Crystal A., Garcia, David A., Garonzik, Samira, Lopes, Renato D., Mahaffey, Kenneth W., Matsuda, Kelly, Middleton, John P., Rymer, Jennifer A., Sands, George H., Thadhani, Ravi, Thomas, Kevin L., Washam, Jeffrey B., Winkelmayer, Wolfgang C., and Granger, Christopher B.

Published
2022
Full Text
View/download PDF

23. Primary prevention implantable cardioverter defibrillators in end-stage kidney disease patients on dialysis: a matched cohort study

Author

Pun, Patrick H, Hellkamp, Anne S, Sanders, Gillian D, Middleton, John P, Hammill, Stephen C, Al-Khalidi, Hussein R, Curtis, Lesley H, Fonarow, Gregg C, and Al-Khatib, Sana M

Subjects
Cardiovascular, Kidney Disease, Clinical Research, Heart Disease, Prevention, Renal and urogenital, Good Health and Well Being, Aged, Aged, 80 and over, Death, Sudden, Cardiac, Defibrillators, Implantable, Female, Heart Failure, Humans, Incidence, Kidney Failure, Chronic, Male, Middle Aged, Primary Prevention, Propensity Score, Proportional Hazards Models, Registries, Renal Dialysis, Retrospective Studies, cardiovascular disease, defibrillator, dialysis, end-stage kidney disease, sudden cardiac death, Clinical Sciences, Urology & Nephrology
Abstract

BackgroundSudden cardiac death is the leading cause of death among end-stage kidney disease patients (ESKD) on dialysis, but the benefit of primary prevention implantable cardioverter defibrillators (ICDs) in this population is uncertain. We conducted this investigation to compare the mortality of dialysis patients receiving a primary prevention ICD with matched controls.MethodsWe used data from the National Cardiovascular Data Registry's ICD Registry to select dialysis patients who received a primary prevention ICD, and the Get with the Guidelines-Heart Failure Registry to select a comparator cohort. We matched ICD recipients and no-ICD patients using propensity score techniques to reduce confounding, and overall survival was compared between groups.ResultsWe identified 108 dialysis patients receiving primary prevention ICDs and 195 comparable dialysis patients without ICDs. One year (3-year) mortality was 42.2% (68.8%) in the ICD registry cohort compared with 38.1% (75.7%) in the control cohort. There was no significant survival advantage associated with ICD [hazard ratio (HR) 0.87, 95% confidence interval (CI) 0.66-1.13, log-rank P = 0.29]. After propensity matching, our analysis included 86 ICD patients and 86 matched controls. Comparing the propensity-matched cohorts, 1 year (3 years) mortality was 43.4% (74.0%) in the ICD cohort and 39.7% (76.6%) in the control cohort; there was no significant difference in mortality outcome between groups (HR = 0.94, 95% CI: 0.67-1.31, log-rank P = 0.71).ConclusionsWe did not observe a significant association between primary prevention ICDs and reduced mortality among ESKD patients receiving dialysis. Consideration of the potential risks and benefits of ICD implantation in these patients should be undertaken while awaiting the results of definitive clinical trials.

Published
2015

24. Primary Prevention Implantable Cardioverter-Defibrillators in Older Racial and Ethnic Minority Patients

Author

Pokorney, Sean D, Hellkamp, Anne S, Yancy, Clyde W, Curtis, Lesley H, Hammill, Stephen C, Peterson, Eric D, Masoudi, Frederick A, Bhatt, Deepak L, Al-Khalidi, Hussein R, Heidenreich, Paul A, Anstrom, Kevin J, Fonarow, Gregg C, and Al-Khatib, Sana M

Subjects
Prevention, Clinical Research, Heart Disease, Cardiovascular, Good Health and Well Being, Age Factors, Aged, Aged, 80 and over, Comparative Effectiveness Research, Death, Sudden, Cardiac, Defibrillators, Implantable, Electric Countershock, Ethnicity, Healthcare Disparities, Humans, Medicare, Minority Groups, Primary Prevention, Racial Groups, Registries, Risk Factors, Time Factors, Treatment Outcome, United States, continental population groups, death, sudden, defibrillators, implantable ethnology, minority groups, primary prevention, defibrillators, implantable, ethnology, Cardiorespiratory Medicine and Haematology, Clinical Sciences, Medical Physiology, Cardiovascular System & Hematology
Abstract

BackgroundRacial and ethnic minorities are under-represented in clinical trials of primary prevention implantable cardioverter-defibrillators (ICDs). This analysis investigates the association between primary prevention ICDs and mortality among Medicare, racial/ethnic minority patients.Methods and resultsData from Get With The Guidelines-Heart Failure Registry and National Cardiovascular Data Registry's ICD Registry were used to perform an adjusted comparative effectiveness analysis of primary prevention ICDs in Medicare, racial/ethnic minority patients (nonwhite race or Hispanic ethnicity). Mortality data were obtained from the Medicare denominator file. The relationship of ICD with survival was compared between minority and white non-Hispanic patients. Our analysis included 852 minority patients, 426 ICD and 426 matched non-ICD patients, and 2070 white non-Hispanic patients (1035 ICD and 1035 matched non-ICD patients). Median follow-up was 3.1 years. Median age was 73 years, and median ejection fraction was 23%. Adjusted 3-year mortality rates for minority ICD and non-ICD patients were 44.9% (95% confidence interval [CI], 44.2%-45.7%) and 54.3% (95% CI, 53.4%-55.1%), respectively (adjusted hazard ratio, 0.79; 95% CI, 0.63-0.98; P=0.034). White non-Hispanic patients receiving an ICD had lower adjusted 3-year mortality rates of 47.8% (95% CI, 47.3%-48.3%) compared with 57.3% (95% CI, 56.8%-57.9%) for those with no ICD (adjusted hazard ratio, 0.75; 95% CI, 0.67%-0.83%; P

Published
2015

25. Primary Prevention Implantable Cardioverter-Defibrillators and Survival in Older Women

Author

Zeitler, Emily P, Hellkamp, Anne S, Fonarow, Gregg C, Hammill, Stephen C, Curtis, Lesley H, Hernandez, Adrian F, Al-Khalidi, Hussein R, Curtis, Jeptha P, Heidenreich, Paul A, Anstrom, Kevin J, Peterson, Eric D, Mark, Daniel B, Hammill, Bradley G, Sanders, Gillian D, and Al-Khatib, Sana M

Subjects
Aging, Prevention, Clinical Research, Heart Disease, Cardiovascular, Good Health and Well Being, Adrenergic beta-Antagonists, Aged, Aged, 80 and over, Angiotensin Receptor Antagonists, Defibrillators, Implantable, Female, Heart Failure, Humans, Male, Primary Prevention, Propensity Score, Registries, United States, Ventricular Dysfunction, Left, heart failure, implantable cardioverter-defibrillator, mortality, primary prevention, women, Heart failure, Implantable cardioverter-defibrillator, Mortality, Primary prevention, Women, Cardiorespiratory Medicine and Haematology
Abstract

ObjectivesThe purpose of this study was to assess the benefit of primary prevention implantable cardioverter defibrillators (ICDs) in women.BackgroundClinical trials of primary prevention ICDs enrolled a limited number of women.MethodsUsing a propensity score method, we matched 490 women ≥65 years of age who received an ICD during a hospitalization for heart failure in the National Cardiovascular Data Registry ICD Registry from January 1, 2006, through December 31, 2007, to 490 ICD-eligible women without an ICD hospitalized for heart failure in the Get With The Guidelines for Heart Failure database from January 1, 2006, through December 31, 2009. The primary endpoint was all-cause mortality obtained from the Medicare Claims Database. An identical analysis was conducted in men.ResultsMedian follow-up for patients with an ICD was 4.6 years versus 3.2 years for patients with no ICD. Compared with women with no ICD, those with an ICD were younger and less frequently white. In the matched cohorts, the survival of women with an ICD was significantly longer than that of women without an ICD (adjusted hazard ratio: 0.79, 95% confidence interval: 0.66 to 0.95; p = 0.013). Similarly, men with an ICD had longer survival than men without an ICD (adjusted hazard ratio: 0.73, 95% confidence interval: 0.65 to 0.83; p < 0.0001). There was no interaction between sex and the presence of an ICD with respect to survival (p = 0.44).ConclusionsAmong older women with left ventricular dysfunction, a primary prevention ICD was associated with a significant survival benefit that was nearly identical to that seen in men. These findings support the use of primary prevention ICDs in eligible patients regardless of sex.

Published
2015

26. CABG Improves Outcomes in Patients With Ischemic Cardiomyopathy: 10-Year Follow-Up of the STICH Trial

Author

Howlett, Jonathan G., Stebbins, Amanda, Petrie, Mark C., Jhund, Pardeep S., Castelvecchio, Serenella, Cherniavsky, Alexander, Sueta, Carla A., Roy, Ambuj, Piña, Ileana L., Wurm, Raphael, Drazner, Mark H., Andersson, Bert, Batlle, Carmen, Senni, Michele, Chrzanowski, Lukasz, Merkely, Bela, Carson, Peter, Desvigne-Nickens, Patrice M., Lee, Kerry L., Velazquez, Eric J., and Al-Khalidi, Hussein R.

Published
2019
Full Text
View/download PDF

28. Association Between Prophylactic Implantable Cardioverter-Defibrillators and Survival in Patients With Left Ventricular Ejection Fraction Between 30% and 35%

Author

Al-Khatib, Sana M, Hellkamp, Anne S, Fonarow, Gregg C, Mark, Daniel B, Curtis, Lesley H, Hernandez, Adrian F, Anstrom, Kevin J, Peterson, Eric D, Sanders, Gillian D, Al-Khalidi, Hussein R, Hammill, Bradley G, Heidenreich, Paul A, and Hammill, Stephen C

Subjects
Cardiovascular, Clinical Research, Bioengineering, Heart Disease, Aged, Aged, 80 and over, Cohort Studies, Defibrillators, Implantable, Female, Heart Failure, Humans, Male, Medicare, Propensity Score, Registries, Retrospective Studies, Risk, Survival Analysis, United States, Ventricular Dysfunction, Left, Ventricular Function, Left, Medical and Health Sciences, General & Internal Medicine
Abstract

ImportanceClinical trials of prophylactic implantable cardioverter-defibrillators (ICDs) have included a minority of patients with a left ventricular ejection fraction (LVEF) between 30% and 35%. Because a large number of ICDs in the United States are implanted in such patients, it is important to study survival associated with this therapy.ObjectiveTo characterize patients with LVEF between 30% and 35% and compare the survival of those with and without ICDs.Design, setting, and participantsRetrospective cohort study of Medicare beneficiaries in the National Cardiovascular Data Registry ICD registry (January 1, 2006, through December 31, 2007) with an LVEF between 30% and 35% who received an ICD during a heart failure hospitalization and similar patients in the Get With The Guidelines-Heart Failure (GWTG-HF) database (January 1, 2005, through December 31, 2009) with no ICD. The analysis was repeated in patients with an LVEF less than 30%. There were 3120 patients with an LVEF between 30% and 35% (816 in matched cohorts) and 4578 with an LVEF less than 30% (2176 in matched cohorts). Propensity score matching and Cox models were applied.Main outcomes and measuresThe primary outcome was all-cause mortality; data were obtained from Medicare claims through December 31, 2011.ResultsThere were no significant differences in the baseline characteristics of the matched groups (n = 408 for both groups). Among patients with an LVEF between 30% and 35%, there were 248 deaths in the ICD Registry group, within a median follow-up of 4.4 years (interquartile range, 2.7-4.9) and 249 deaths in the GWTG HF group, within a median follow-up of 2.9 years (interquartile range, 2.1-4.4). The risk of all-cause mortality in patients with an LVEF between 30% and 35% and an ICD was significantly lower than that in matched patients without an ICD (3-year mortality rates: 51.4% vs 55.0%; hazard ratio, 0.83 [95% CI, 0.69-0.99]; P = .04). Presence of an ICD also was associated with better survival in patients with an LVEF less than 30% (3-year mortality rates: 45.0% vs 57.6%; 634 and 660 total deaths; hazard ratio, 0.72 [95% CI, 0.65-0.81]; P

Published
2014

29. Detection of brain lesions after catheter ablation depends on imaging criteria – Insights from AXAFA-AFNET 5 trial

Author

Haeusler, Karl Georg, primary, Eichner, Felizitas A, additional, Heuschmann, Peter U, additional, Fiebach, Jochen B, additional, Engelhorn, Tobias, additional, Callans, David, additional, De Potter, Tom, additional, Debruyne, Philippe, additional, Scherr, Daniel, additional, Hindricks, Gerhard, additional, Al-Khalidi, Hussein R, additional, Mont, Lluis, additional, Kim, Won Yong, additional, Piccini, Jonathan P, additional, Schotten, Ulrich, additional, Themistoclakis, Sakis, additional, Di Biase, Luigi, additional, and Kirchhof, Paulus, additional

Published
2023
Full Text
View/download PDF

32. Impact of Intubation Time on Survival following Coronary Artery Bypass Grafting: Insights from the Surgical Treatment for Ischemic Heart Failure (STICH) Trial

Author

Bouabdallaoui, Nadia, Stevens, Susanna R., Doenst, Torsten, Wrobel, Krzysztof, Bouchard, Denis, Deja, Marek A., Michler, Robert E., Chua, Yeow Leng, Kalil, Renato A.K., Selzman, Craig H., Daly, Richard C., Sun, Benjamin, Djokovic, Ljubomir T., Sopko, George, Velazquez, Eric J., Rouleau, Jean L., Lee, Kerry L., and Al-Khalidi, Hussein R.

Published
2018
Full Text
View/download PDF

34. A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial

Author

Piccini, Jonathan P., Connolly, Stuart J., Abraham, William T., Healey, Jeff S., Steinberg, Benjamin A., Al-Khalidi, Hussein R., Dignacco, Patricia, van Veldhuisen, Dirk J., Sauer, William H., White, Michel, Wilton, Stephen B., Anand, Inder S., Dufton, Christopher, Marshall, Debra A., Aleong, Ryan G., Davis, Gordon W., Clark, Richard L., Emery, Laura L., and Bristow, Michael R.

Published
2018
Full Text
View/download PDF

35. Apixaban or Warfarin in Patients with an On-X Mechanical Aortic Valve

Author

Wang, Tracy Y., primary, Svensson, Lars G., additional, Wen, Jun, additional, Vekstein, Andrew, additional, Gerdisch, Marc, additional, Rao, Vijay U., additional, Moront, Michael, additional, Johnston, Doug, additional, Lopes, Renato D., additional, Chavez, Alma, additional, Ruel, Marc, additional, Blackstone, Eugene H., additional, Becker, Richard C., additional, Thourani, Vinod, additional, Puskas, John, additional, Al-Khalidi, Hussein R., additional, Cable, David G., additional, Elefteriades, John A., additional, Pochettino, Alberto, additional, Wolfe, J. Alan, additional, Graeve, Allen, additional, Sultan, Ibrahim, additional, Sabe, Ashraf A., additional, Michelena, Hector I., additional, and Alexander, John H., additional

Published
2023
Full Text
View/download PDF

36. A multifaceted intervention to improve treatment with oral anticoagulants in atrial fibrillation (IMPACT-AF): an international, cluster-randomised trial

Author

Carbajales, Justo, Gómez, Javier Neri Ceferino, Principato, Mario Bruno, Von Wulffen, María Alejandra, Acunzo, Jorge Galperín Rafael Salvador, Bonato, Ricardo Renato, Ciampi, Natalia, Marani, Alberto Babil, Panigadi, Cristian Gustavo, Pastura, Silvia Gabriela, Onetto, Leonardo Martín, Moya, Cecilia Rafaela, Budassi, Nadia, Valle, Marisol, Camerini, Daniel, Monjes, Enrique, Zabala, Federico, Ricart, Juan Pablo, Medesani, Luis, Campos, Eduardo Noe Ortuño, Ferroni, Fabián, Torres, Mariana Foa, Fassi, Daniel Omar, Bosio, Fernando Javier Díaz, Baztarrica, Gabriel Edgardo Pérez, Infantas, Teresa Zúñiga, Perlo, Daniela, García, Celso Fernando, Durán, Rubén García, Durán, Luisina García, Pettinari, Cecilia Alejandra, Vico, Marisa Liliana, Lanchiotti, Paulina Virginia, Gómez, Mariela Soledad, Poy, Carlos Alberto, Grazziani, Franco Sebastián, Laspina, Marcela Julieta, Poy, María Laura, Bahit, María Cecilia, Tajer, Carlos, García, Marilia, Lopes, Renato D., de Barros e Silva, Pedro Gabriel Melo, Berwanger, Otavio, Egydio, Flávia, Restelli, Elissa, Kawakami, Anelise, Soares, Tamara Colaiácovo, Valois, Mayara Vioto, Duarte, Tauane Bello, Barbosa, Lilian Mazza, de Paola, Angelo Amato Vicenzo, Pimenta, Thiago Librelon, Jeronimo, Gabriela Dal Moro, da Costa, Bruna S. Fernandes, Coutinho, Enia Lucia, Guerrero, Andressa Zulmira A., Maia, Lilia Nigro, Nakazone, Marcelo Arruda, Lemos, Maria Angelica Teixeira, Costa, Osana Maria Coelho, Demore, Ana Paula, Brito, Roberta Parra, Melo, Camila Dal Bon, Góes, Nadielly Codonho, Lorenço, Osvaldo, Gonçalves, Luiz Otavio Maia, Nishiama, Kátia, de Lima, Tiago Aparecido Maschio, Backes, Luciano Marcelo, de Lima Deucher, Keyla Liliana Alves, Rodrigues, Milena Pozzatto, Baldissera, Dunnia Monisa, Reolão, José Basileu Caos, dos Santos, Tais Alves, Freisleben, Fernanda Michel Birck, da Silveira Kaross, Níncia Lucca, Montovani, Jéssika Tzervieczenski, Cantarelli, Maiara, Lucion, Aline, do Amarante, Luciano, Foscarini, Priscila, de Mello Perez, Claudia, França, Fernanda Ribeiro, Fialho, Lisa, Rey, Helena Cramer Veiga, God, Epotamenides Maria Good, Figueiredo, Estêvão Lanna, Werner, Gustavo Fonseca, de Faria Garcia, Jose Carlos, Azevedo, Bruna, Barbosa, Luiz Carlos Vianna, Pardi, Ernaldo, Oliveira, Márcia Domingos, Martinelli, Toshie, Cavalini, Roseli Gomes, de Moraes, Michele Santos Montoni, Filho, Adalberto Menezes Lorga, Palmegiani, Eduardo, Megid, Thiago Baccilli Cury, Queirantes, Clotildes S.P., Cruz, Thamyres Santini Arroyo, He, Pengkang, Zhou, Xiaolan, Zhou, Na, Zhao, Mingzhong, Yu, Juan, Cheng, Yong, Wang, Lijun, Liu, Lili, Liu, Shuwang, Li, Lei, Li, Aihua, Yuan, Xiaochen, Xia, Guangwei, Wang, Zhirong, Li, Chengzong, Chen, Wensu, Tang, Qiang, Tang, Qunzhong, Xu, Weiting, Zhu, Xinyi, Hou, Bin, Ma, Wenjian, Wang, Chongquan, Jin, Qiaoyun, Wang, Jianan, Xie, Xiaojie, Joseph, Johny, Davidson, Deepak, Thomas, Joby K., Kunjumon, Tony V., Stephen, Tibin, Fatania, Kamlesh, Rathi, Gaurav, Garala, Kinjal, Doshi, Dhruval, Varghese, Kiron, MA, Srilakshmi, Sheeba, Lumin, Kumar, Shantha, Rao, Malipeddi Bhaskara, Rao, Kodem Damodara, Vuriya, Anjan Kumar, Kumari, Mandula Padma, Khandelwal, Bidita, Dhakal, Mona, Srivastava, Nitin, Khatri, Dheeraj, Moktan, Shova, Gupta, Rajeev, Roy, Sanjeeb, Kumawat, Kapil, Sharma, Mukesh, Sharma, K.K., Jathappa, Narendra, Lokesh, B.H., Kariyappa, Shilpa, Leela, A.C., Someshwara, K.C., Desai, Soaham, Desai, Devangi, Patel, Kunj, Patel, Sujal, Bhartiya, Maulik, Mahanta, Bhupendra Narayan, Dutta, Dibya Jyoti, Rajkonwer, Ghanashyam, Gupta, Sandeep Kumar, Mishra, Ashok Kumar, Singh, Akansha, Kesarwani, Naveen, Kumar, Shivendra, Chioncel, Ovidiu, Balan, Adriana, Carstea, Nicolae, Chitoiu, Gabriel Tatu, Cornaciu, Stelian, Cinteza, Mircea, Rimbas, Roxana C., Dimulescu, Doina, Ionescu, Luminita, Fruntelata, Ana, Dumitru, Nicoleta, Gaita, Dan, Pleava, Roxana, Iliesiu, Adriana, Uscoiu, Gabriela, Lighezan, Daniel, Buzas, Roxana, Sinescu, Crina J., Avram, Ana-Maria, Baldea, Sorina, Galrinho, Ruxandra Dragoi, Magda, Stefania L., Matei, Lavinia, Vinereanu, Dragos, Lopes, Renato D, Bahit, M Cecilia, Xavier, Denis, Jiang, Jie, Al-Khalidi, Hussein R, He, Wensheng, Xian, Ying, Ciobanu, Andrea O, Kamath, Deepak Y, Fox, Kathleen A, Rao, Meena P, Pokorney, Sean D, de Barros e Silva, Pedro G M, Roettig, Mayme L, Huo, Yong, and Granger, Christopher B

Published
2017
Full Text
View/download PDF

37. Safety of coronary CT angiography and functional testing for stable chest pain in the PROMISE trial: A randomized comparison of test complications, incidental findings, and radiation dose

Author

Lu, Michael T., Douglas, Pamela S., Udelson, James E., Adami, Elizabeth, Ghoshhajra, Brian B., Picard, Michael H., Roberts, Rhonda, Lee, Kerry L., Einstein, Andrew J., Mark, Daniel B., Velazquez, Eric J., Carter, William, Ridner, Michael, Al-Khalidi, Hussein R., and Hoffmann, Udo

Published
2017
Full Text
View/download PDF

39. Catheterization Laboratory Activation Time in Patients Transferred With ST-Segment–Elevation Myocardial Infarction: Insights From the Mission: Lifeline STEMI Accelerator-2 Project

Author

Zeitouni, Michel, Al-Khalidi, Hussein R., Roettig, Mayme L., Bolles, Michele M., Doerfler, Shannon M., Fordyce, Christopher B., Hellkamp, Anne S., Henry, Timothy D., Magdon-Ismail, Zainab, Monk, Lisa, Nelson, R. Darrell, O’Brien, Peter K., Wilson, B. Hadley, Ziada, Khaled M., Granger, Christopher B., and Jollis, James G.

Published
2020
Full Text
View/download PDF

40. Comparison of an initial risk-based testing strategy vs usual testing in stable symptomatic patients with suspected coronary artery disease: the PRECISE randomized ttrial

Author

Douglas, Pamela S., Nanna, Michael G., Kelsey, Michelle D., Yow, Eric, Mark, Daniel B., Patel, Manesh R., Rogers, Campbell, Udelson, James E., Fordyce, Christopher B., Curzen, Nicholas, Pontone, Gianluca, Maurovich-Horvat, Pal, De Bruyne, Bernard, Greenwood, John P., Marinescu, Victor, Leipsic, Jonathon, Stone, Gregg W., Ben-Yehuda, Ori, Berry, Colin, Hogan, Shea E., Redfors, Bjorn, Ali, Ziad A., Byrne, Robert A., Kramer, Christopher M., Yeh, Robert W., Martinez, Beth, Mullen, Sarah, Huey, Whitney, Anstrom, Kevin J., Al-Khalidi, Hussein R., and Vemulapalli, Sreekanth

Published
2023

41. Deferred testing in stable outpatients with suspected coronary artery disease: a prespecified secondary analysis of the PRECISE randomized clinical trial

Author

Udelson, James E., Kelsey, Michelle D., Nanna, Michael G., Fordyce, Christopher B., Yow, Eric, Clare, Robert M., Mark, Daniel B., Patel, Manesh R., Rogers, Campbell, Curzen, Nicholas, Pontone, Gianluca, Maurovich-Horvat, Pal, De Bruyne, Bernard, Greenwood, John P., Marinescu, Victor, Leipsic, Jonathon, Stone, Gregg W., Ben-Yehuda, Ori, Berry, Colin, Hogan, Shea E., Redfors, Bjorn, Ali, Ziad A., Byrne, Robert A., Kramer, Christopher M., Yeh, Robert W., Martinez, Beth, Mullen, Sarah, Huey, Whitney, Anstrom, Kevin J., Al-Khalidi, Hussein R., Chiswell, Karen, Vemulapalli, Sreekanth, and Douglas, Pamela S.

Abstract

Importance: guidelines recommend deferral of testing for symptomatic people with suspected coronary disease (CAD) and low pretest probability. No randomized trial has prospectively evaluated such a strategy.Objective: to assess process of care and health outcomes in people identified as minimal risk for CAD when testing is deferred.Design: randomized, pragmatic effectiveness trial.Setting: prespecified subgroup analysis of the PRECISE trial, at 65 North American and European sites. Participants: identified as minimal risk by the validated PROMISE Minimal Risk Score (PMRS).Intervention: randomization to a precision strategy using the PMRS to assign those with minimal risk to deferred testing and others to coronary CTA with selective CT-derived fractional flow reserve, or to usual testing (stress testing or catheterization, with PMRS blinded). Randomization was stratified by PMRS risk.Main outcome: composite of all-cause death, nonfatal myocardial infarction (MI), or catheterization without obstructive CAD through 12 months.Results: among 2103 participants, 422 (20%) were identified as minimal risk and randomized to deferred testing (n=214) or usual testing (n=208). Mean age (SD) was 46 (8.6) years; 72% were women. During follow-up, 138 (64%) of those randomized to deferred testing never had testing,whereas 76 (36%) had a downstream test (at median [IQR] 48 [15, 78] days) for worsening (30%), uncontrolled (10%), or new (6%) symptoms or changing provider (19%) or participant (10%) preference. Results were normal for 96% of these tests. The primary endpoint occurred in 2 (0.9%) deferred testing and 13 (6.3%) usual testing participants, HR (95% CI) 0.15 (0.03, 60.66), p=0.012. No death or MI was observed in the deferred testing participants, while 1noncardiovascular death and 1 MI occurred in the usual testing group. Two participants hadcatheterizations without obstructive CAD in the deferred testing group and 12 with usual testing (p=0.016). At baseline, 70% of participants had frequent angina, and there was similar reduction of frequent angina to Conclusion and relevance: in symptomatic participants with suspected CAD, identification of minimal risk by the PMRS guided a strategy of initially deferred testing. The strategy was safe with no observed adverse outcome events, fewer catheterizations without obstructive CAD, and similar symptom relief compared with usual testing.Trial registration: ClinicalTrials.Gov NCT03702244.

Published
2023

43. The RENEW Trial: Efficacy and Safety of Intramyocardial Autologous CD34+ Cell Administration in Patients With Refractory Angina

Author

Povsic, Thomas J., Henry, Timothy D., Traverse, Jay H., Fortuin, F. David, Schaer, Gary L., Kereiakes, Dean J., Schatz, Richard A., Zeiher, Andreas M., White, Christopher J., Stewart, Duncan J., Jolicoeur, E. Marc, Bass, Theodore, Henderson, David A., Dignacco, Patricia, Gu, Ziangoiong, Al-Khalidi, Hussein R., Junge, Candice, Nada, Adel, Hunt, Andrea S., and Losordo, Douglas W.

Published
2016
Full Text
View/download PDF

46. Risk Factors for Increased Stent-Associated Symptoms Following Ureteroscopy for Urinary Stones: Results from STENTS

Author

Harper, Jonathan D., primary, Desai, Alana C., additional, Maalouf, Naim M., additional, Yang, Hongqiu, additional, Antonelli, Jodi A., additional, Tasian, Gregory E., additional, Lai, H. Henry, additional, Reese, Peter P., additional, Curatolo, Michele, additional, Kirkali, Ziya, additional, Al-Khalidi, Hussein R., additional, Wessells, Hunter, additional, and Scales, Charles D., additional

Published
2023
Full Text
View/download PDF

48. Optimal medical therapy with or without surgical revascularization and long-term outcomes in ischemic cardiomyopathy

Author

Farsky, Pedro S., primary, White, Jennifer, additional, Al-Khalidi, Hussein R., additional, Sueta, Carla A., additional, Rouleau, Jean L., additional, Panza, Julio A., additional, Velazquez, Eric J., additional, O'Connor, Christopher M., additional, Dabrowski, Rafal, additional, Djokovic, Ljubomir, additional, Drazner, Mark, additional, Haddad, Haissam, additional, Ali, Imtiaz S., additional, Keltai, Matyas, additional, Naik, Ajay, additional, Sopko, George, additional, Golba, Krzysztof, additional, Andersson, Bert, additional, Carson, Peter, additional, and Kukulski, Tomasz, additional

Published
2022
Full Text
View/download PDF

49. Abatacept for Treatment of Adults Hospitalized with Moderate or Severe Covid-19

Author

Ko, Emily R., Anstrom, Kevin J., Panettieri, Reynold A., Lachiewicz, Anne M., Maillo, Martin, O’Halloran, Jane A., Boucher, Cynthia, Smith, P. Brian, McCarthy, Matthew W., Segura Nunez, Patricia, Mendivil Tuchia de Tai, Sabina, Khan, Akram, Mena Lora, Alfredo J., Salathe, Matthias, Kedar, Eyal, Capo, Gerardo, Rodríguez Gonzalez, Daniel, Patterson, Thomas F., Palma, Christopher, Ariza, Horacio, Patelli Lima, Maria, Blamoun, John, Nannini, Esteban C., Sprinz, Eduardo, Mykietiuk, Analia, Wang, Jennifer P., Parra-Rodriguez, Luis, Der, Tatyana, Willsey, Kate, Benjamin, Daniel K., Wen, Jun, Zakroysky, Pearl, Halabi, Susan, Silverstein, Adam, McNulty, Steven E., O’Brien, Sean M., Al-Khalidi, Hussein R., Butler, Sandra, Atkinson, Jane, Adam, Stacey J., Chang, Soju, Maldonado, Michael A., Proscham, Michael, LaVange, Lisa, Bozzette, Samuel A., and Powderly, William G.

Subjects
Article
Abstract

BackgroundWe investigated whether abatacept, a selective costimulation modulator, provides additional benefit when added to standard-of-care for patients hospitalized with Covid-19.MethodsWe conducted a master protocol to investigate immunomodulators for potential benefit treating patients hospitalized with Covid-19 and report results for abatacept. Intravenous abatacept (one-time dose 10 mg/kg, maximum dose 1000 mg) plus standard of care (SOC) was compared with shared placebo plus SOC. Primary outcome was time-to-recovery by day 28. Key secondary endpoints included 28-day mortality.ResultsBetween October 16, 2020 and December 31, 2021, a total of 1019 participants received study treatment (509 abatacept; 510 shared placebo), constituting the modified intention-to-treat cohort. Participants had a mean age 54.8 (SD 14.6) years, 60.5% were male, 44.2% Hispanic/Latino and 13.7% Black. No statistically significant difference for the primary endpoint of time-to-recovery was found with a recovery-rate-ratio of 1.14 (95% CI 1.00–1.29; p=0.057) compared with placebo. We observed a substantial improvement in 28-day all-cause mortality with abatacept versus placebo (11.0% vs. 15.1%; odds ratio [OR] 0.62 [95% CI 0.41– 0.94]), leading to 38% lower odds of dying. Improvement in mortality occurred for participants requiring oxygen/noninvasive ventilation at randomization. Subgroup analysis identified the strongest effect in those with baseline C-reactive protein >75mg/L. We found no statistically significant differences in adverse events, with safety composite index slightly favoring abatacept. Rates of secondary infections were similar (16.1% for abatacept; 14.3% for placebo).ConclusionsAddition of single-dose intravenous abatacept to standard-of-care demonstrated no statistically significant change in time-to-recovery, but improved 28-day mortality.Trial registrationClinicalTrials.gov(NCT04593940).

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results